Jain Ankit, Jain Sanjay K
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, Sagar (M.P.), India.
Crit Rev Ther Drug Carrier Syst. 2015;32(2):149-80. doi: 10.1615/critrevtherdrugcarriersyst.2015010903.
Delivering therapeutics across the blood brain barrier (BBB) remains the rate-limiting step in brain medicine research. Three main categories of endogenous transportation at BBB that can be used for targeting brain are carrier-mediated transport, active efflux transport, and receptor-mediated transport. Various approaches using nanocarriers such as liposomes, niosomes, micelles, and nanoparticles with manifested surface modifications using either covalent or noncovalent methods to append suitable ligands are being intensively explored to achieve drug delivery to the brain. Harvested ligands include peptide, glutathione, transferrin, and transferrin antibody, lectins, lactic acid, cholera toxin B, etc. In this review, we present recent insights into the development of safe and efficient brain drug delivery as well as recent advances in BBB targeting tactics including antibody-directed enzyme prodrug therapy, a biotin-avidin conjugated system, and chimeric peptides. This review serves as an excellent source of knowledge for budding brain researchers.
跨越血脑屏障（BBB）递送治疗药物仍然是脑医学研究中的限速步骤。血脑屏障处可用于靶向脑部的内源性转运主要有三类：载体介导的转运、主动外排转运和受体介导的转运。人们正在深入探索各种使用纳米载体的方法，如脂质体、非离子型脂质体、胶束和纳米颗粒，通过共价或非共价方法进行明显的表面修饰以连接合适的配体，从而实现向脑部递送药物。收获的配体包括肽、谷胱甘肽、转铁蛋白和转铁蛋白抗体、凝集素、乳酸、霍乱毒素B等。在本综述中，我们介绍了关于安全高效脑药物递送发展的最新见解以及血脑屏障靶向策略的最新进展，包括抗体导向酶前药疗法、生物素-抗生物素蛋白共轭系统和嵌合肽。这篇综述为初露头角的脑研究人员提供了极好的知识来源。
